Alaa Quisi1, Gökhan Alıcı2. 1. Department of Cardiology, Medline Adana Hospital, Adana, Turkey. 2. Department of Cardiology, Yüksekova State Hospital, Hakkari, Turkey.
Abstract
OBJECTIVE: This study aimed to evaluate the relationship between serum rheumatoid factor (RF) levels and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). METHODS: This single-center, cross-sectional study included a total of 318 consecutive patients who were diagnosed with STEMI and underwent primary PCI within 12 hours of the onset of symptoms. Baseline serum RF levels of all patients were measured. The diagnosis of no-reflow phenomenon was defined as a flow of TIMI II or less without the presence of dissection, mechanical obstruction, significant residual stenosis, or other plausible causes. The patients were divided into reflow group (n = 283) and no-reflow group (n = 46) regarding the angiographic features of thrombolysis in myocardial infarction (TIMI) flow of the infarct-related artery. RESULTS: No-reflow phenomenon was observed in 13.8% of the patients. Median RF level was significantly higher in no-reflow group than in reflow group (18.5 (7.0-27.6) vs 8.0 (4.6-50.8), P < .001). Forward conditional logistic regression analysis demonstrated that body mass index (OR = 0.845, 95% CI: 0.765 to 0.933, P = .001), diabetes mellitus (OR = 5.257, 95% CI: 1.124 to 24.587, P = .035), baseline RF level (OR = 1.198, 95% CI: 1.108 to 1.295, P < .001), and SYNTAX score I (OR = 1.065, 95% CI: 1.025 to 1.107, P = .001) were the independent predictors of no-reflow phenomenon. CONCLUSION: Baseline serum RF concentrations are independently associated with the no-reflow phenomenon in patients undergoing primary PCI for acute STEMI.
OBJECTIVE: This study aimed to evaluate the relationship between serum rheumatoid factor (RF) levels and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). METHODS: This single-center, cross-sectional study included a total of 318 consecutive patients who were diagnosed with STEMI and underwent primary PCI within 12 hours of the onset of symptoms. Baseline serum RF levels of all patients were measured. The diagnosis of no-reflow phenomenon was defined as a flow of TIMI II or less without the presence of dissection, mechanical obstruction, significant residual stenosis, or other plausible causes. The patients were divided into reflow group (n = 283) and no-reflow group (n = 46) regarding the angiographic features of thrombolysis in myocardial infarction (TIMI) flow of the infarct-related artery. RESULTS: No-reflow phenomenon was observed in 13.8% of the patients. Median RF level was significantly higher in no-reflow group than in reflow group (18.5 (7.0-27.6) vs 8.0 (4.6-50.8), P < .001). Forward conditional logistic regression analysis demonstrated that body mass index (OR = 0.845, 95% CI: 0.765 to 0.933, P = .001), diabetes mellitus (OR = 5.257, 95% CI: 1.124 to 24.587, P = .035), baseline RF level (OR = 1.198, 95% CI: 1.108 to 1.295, P < .001), and SYNTAX score I (OR = 1.065, 95% CI: 1.025 to 1.107, P = .001) were the independent predictors of no-reflow phenomenon. CONCLUSION: Baseline serum RF concentrations are independently associated with the no-reflow phenomenon in patients undergoing primary PCI for acute STEMI.
Authors: R Montisci; A Vacca; P Garau; P Colonna; M Ruscazio; G Passiu; S Iliceto; A Mathieu Journal: Ann Rheum Dis Date: 2003-09 Impact factor: 19.103
Authors: Paul Sorajja; Bernard J Gersh; Costantino Costantini; Michael G McLaughlin; Peter Zimetbaum; David A Cox; Eulogio Garcia; James E Tcheng; Roxana Mehran; Alexandra J Lansky; David E Kandzari; Cindy L Grines; Gregg W Stone Journal: Eur Heart J Date: 2005-02-25 Impact factor: 29.983
Authors: Gjin Ndrepepa; Klaus Tiroch; Massimiliano Fusaro; Dritan Keta; Melchior Seyfarth; Robert A Byrne; Jürgen Pache; Patricia Alger; Julinda Mehilli; Albert Schömig; Adnan Kastrati Journal: J Am Coll Cardiol Date: 2010-05-25 Impact factor: 24.094
Authors: Robert W Harrison; Atul Aggarwal; Fang-shu Ou; Lloyd W Klein; John S Rumsfeld; Matthew T Roe; Tracy Y Wang Journal: Am J Cardiol Date: 2012-10-27 Impact factor: 2.778